Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 3Lung Neoplasms 3Stomatitis 2Recurrence 2Nasopharyngeal Carcinoma 2Head and Neck Neoplasms 2Breast Neoplasms 2Vitamin B 12 Deficiency 1Urinary Bladder Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Smoking 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Oligodendroglioma 1Nasopharyngeal Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell 1Laryngeal Diseases 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Brain Edema 1Astrocytoma 1

Interventions

Vitamin B 12 1Folic Acid 1Erlotinib Hydrochloride 1Budesonide 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Smoking × Vitamin B 12 × Clear all
NCT00606502 2021-03-05

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
201 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Smoking

Data powered by HemOnc (CC BY 4.0) Colophon âš¡